Solid Biosciences Replaces Exhausted $85M ATM with New $200M Equity Program

summarizeSummary

Solid Biosciences filed a prospectus supplement for a new $200 million at-the-market equity program, replacing its fully utilized $85 million ATM. The program provides flexible capital but introduces potential dilution over time.

check_boxKey Events · Financing and Capital Events · SLDB

• New $200M ATM Program Established

  A prospectus supplement has been filed for a new at-the-market equity program, allowing Solid Biosciences to sell up to $200 million of common stock through Jefferies LLC. This replaces the prior $85 million ATM, which is now fully utilized.

• Prior $85M ATM Fully Drawn

  The company had previously sold approximately $85 million in shares under the prior ATM program, exhausting its capacity.

• Potential Dilution Overhang

  At the current stock price of $8.25, the $200 million program could result in the issuance of approximately 24.2 million shares, representing roughly 23% of the current shares outstanding, though sales will occur over time.

• Funding for Gene Therapy Pipeline

  The ATM provides flexible capital to support ongoing R&D, including the company's Duchenne muscular dystrophy gene therapy programs, as losses widen.

auto_awesomeAnalysis · SLDB · Life Sciences

Solid Biosciences has established a new $200 million at-the-market (ATM) equity offering program, replacing its prior $85 million ATM, which is now fully drawn. The new program allows the company to sell shares into the market from time to time, providing a flexible capital-raising tool. While the ATM structure avoids a large one-time dilutive event, it creates an overhang that could pressure the stock as shares are sold. The move follows a recent doubling of authorized shares and comes amid widening quarterly losses, suggesting the company is proactively securing funding to extend its cash runway for gene therapy development.